Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.
Details of the events are as follows:
Event: Biotech Showcase
Date: January 10-12, 2022
Registration
Event: H.C. Wainwright BioConnect
Date: January 10-13, 2022
Registration
Event: BIO Partnering at JPM
Date: January 10-14, 2022
Registration
During the conference events, members of the Diffusion management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies.
Registered attendees in the H.C. Wainwright BioConnect conference will be able to view a prerecorded, virtual presentation by Diffusion CEO Robert Cobuzzi, Jr., Ph.D. highlighting Diffusion’s business and recent corporate achievements, including the recently announced dosing of the first participants and patients in its last two Oxygenation Trials, the Altitude and ILD-DLCO Trials, with its lead product candidate, trans sodium crocetinate, or TSC. Dr. Cobuzzi also will describe certain aspects of the Company’s rationale for its plans to design and execute a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions, including hypoxic solid tumors. In November 2021, based on the preclinical and clinical data accumulated to date and the significant unmet medical need, Diffusion announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.